top of page
Guest speaker, Oral abstract and Video abstract presenters
Helen MacKay, BSc, MD, MB,ChB, MRCP, Head, Division of Medical Oncology & Hematology, Sunnybrook Health Sciences Centre
Dr. Helen MacKay is a Medical Oncologist and Professor of Medicine at the University of Toronto. She is Head of the Division of Medical Oncology and Hematology at the Odette Cancer Centre at Sunnybrook Health Sciences Centre, and Senior Scientist at the Sunnybrook Research Institute. Dr. MacKay's clinical practice and research focus is on gynecological cancers. Her research involves collaborating with translational and basic scientists in the development and validation of novel therapeutic strategies. She is the current President of the Society of Gynecologic Oncologists of Canada (GOC). She co-chairs the NCI (US), Ovarian Cancer Task Force. She also chairs the Ovarian Group and sits on the executive of the Gyne committee of the Canadian Cancer Trials Group (CCTG), and represents CCTG at the Gynecologic Cancer Intergroup. She is a past chair of both the Gynecologic Cancer Education and Scientific Committees for ASCO. With specific reference to uterine cancers, she is a member of the TRANSPORTEC group, and sits on the Corpus Committee of NRG, and was the co-chair of the NCI Endometrial Cancer Clinical Trials Planning Committee.
Carien Creutzberg, MD PhD, Prof, Radiation Oncologist at Leiden University Medical Centre
Carien Creutzberg is Professor of Radiation Oncology at Leiden University Medical Center, is specialised in research and treatment of gynaecological cancers, and has been initiator and
principal investigator of the four PORTEC trials. She is member of the Dutch Cancer Society Advisory Board, chair of the GCIG Endometrial Cancer Committee, and has been Council member of ESGO and IGCS, and ESMO Faculty Member for the Gynaecological Cancer Track. Her research inradiation therapy for endometrial cancer has had impact on treatment guidelines and research programs for Endometrial Cancer worldwide.
principal investigator of the four PORTEC trials. She is member of the Dutch Cancer Society Advisory Board, chair of the GCIG Endometrial Cancer Committee, and has been Council member of ESGO and IGCS, and ESMO Faculty Member for the Gynaecological Cancer Track. Her research inradiation therapy for endometrial cancer has had impact on treatment guidelines and research programs for Endometrial Cancer worldwide.
Zbigniew Marchocki, MD, MSc, Fellow at Princess Margaret Cancer Centre
Dr. Zibi Marchocki is a second year Clinical Fellow in Gynecologic Oncology at the University of Toronto working at Princess Margaret Cancer Center, Toronto General Hospital and Sunnybrook Hospital. He graduated from Medical University of Warsaw in Poland and completed a residency programme in Obstetrics and Gynaecology in Ireland. He is a Member of the Royal College of Obstetricians and Gynaecologist in the United Kingdom and Royal College of Physicians of Ireland.
Brenna Swift, MD, MASc, Gynecologic Oncology Fellow, University of Toronto
Brenna Swift is a first year Gynecologic Oncology Fellow at the University of Toronto. She completed residency in Obstetrics & Gynaecology, medical school and a MASc in Biomedical Engineering investigating immunotherapy in cancer at the University of Toronto. Her research interests include surgical innovation and education.
Rachel Soyoun Kim, MD, Gynecology Oncology Fellow
Dr Rachel Kim is a gynecology oncology fellow at University of Toronto. Research interests include cancer genomics and hereditary malignancies.
Sarah Mah, MD, FRCSC, Gynecologic Oncology Fellow at McMaster University
Sarah Mah is a Gynecologic Oncology fellow at McMaster University and concurrently undertaking her MSc in Quality Improvement and Patient Safety through the University of Toronto Institute of Health Policy, Management and Evaluation. She completed her residency at the University of British Columbia.
Justin McGinnis, MD, MSc, FRCSC, Gynecologic Oncologist at University of British Columbia
Dr. Justin McGinnis was the inaugural fellow in the Gynecologic Oncology Fellowship TrainingProgram at McMaster University. During his fellowship he attended the University of Toronto'sDalla Lana School of Public Health where he completed a MSc in Quality Improvement & Patient Safety. He is now a practicing gynecologic oncologist at the BC Cancer Agency and Vancouver Coastal Health and places a strong focus on medical education and healthcare quality improvement.
Shana J Kim, MSc, PhD student at University of Toronto
Shana J Kim, MSc, is a doctoral student in the Dalla Lana School of Public Health Epidemiology program at the University of Toronto. Her research interests focus on the role of modifiable risk factors on female reproductive cancer prevention in high-risk women. Miss Kim also works with one of the world's largest registries of BRCA mutation carriers examining risk factors for hereditary cancer at Women's College Hospital. Miss Kim is a recipient of the Canadian Institutes of Health Research Frederick Banting and Charles Best Canada Graduate Scholarship.
Nupur Dogra, MD, MSc, Resident Physician, University of Toronto
Dr. Dogra graduated from the Bachelor of Health Sciences program at McMaster University where she pursued a specialization in Global Health. She went on to complete a Masters in International
Health Policy at the London School of Economics and Political Science in London, UK. She returned to Canada to pursue medicine at the University of Toronto where she earned her medical degree. She is currently a PGY3 Obstetrics and Gynecology resident at the University of Toronto.
Health Policy at the London School of Economics and Political Science in London, UK. She returned to Canada to pursue medicine at the University of Toronto where she earned her medical degree. She is currently a PGY3 Obstetrics and Gynecology resident at the University of Toronto.
Nourah Ibrahim, MD, University of Maitoba
Completed Medical Degree at Kuwait University and Residency in Obstetrics and Gynecology at McMaster University. Currently completing a fellowship in Gynecology Oncology at the University of Manitoba.
Elisabeth Spenard, Clinical Fellow at University of Toronto
Elisabeth Spénard is a first-year clinical fellow in Gynecologic Oncology at the University of Toronto. She completed her residency program in Obstetrics & Gynecology at the Université de Montréal, from which she graduated in 2020. In parallel with her fellowship program, she is currently pursuing a Master’s in Quality Improvement and Patient Safety at the Institute of Health Policy, Management and Evaluation (IHPME) of the Dalla Lana School of Public Health.
Mark Carey, Gynecologic oncologist at UBC
Dr Carey is a Gynaecologic Oncologist at UBC. He has an interest in molecular oncology, drug prediction and clinical trials in gynaecological cancers.
Taymaa May, MD MSc FRCSC
Dr. Taymaa May is a gynecologic oncologist at Princess Margaret Cancer Center and an associate professor at the University of Toronto. Her research focuses on surgical innovation and translational research in the field of ovarian cancer. Dr. May is the director of clinical specialty programs in the department of surgical oncology and a member of the Princess Margaret executive. Dr. May is the surgical oncology lead for Toronto central south, Cancer Care Ontario, Ontario Health and a member of the Gynecologic Oncology Group of Ontario executive. Dr. May is the current chair of the GOC's Annual General Meeting and is a member of GOC’s board of directors.
Barbara Vanderhyden, Distinguished Professor | Corinne Boyer Chair in Ovarian Cancer Research, University of Ottawa
Overview of Research Interests:
The Vanderhyden lab studies many aspects of ovarian cancer, including the role of specific genes in human ovarian cancer initiation, progression, chemo-sensitivity and prognosis. They create model systems of ovarian cancer to study disease initiation and to test the therapeutic efficacy of novel anti-cancer drugs. They are particularly interested in the role of stem cells in the ovarian and oviductal epithelia and their contribution to cancer initiation. With a growing interest in chromatin remodeling proteins, they are exploring the roles of these proteins in reproductive tissues, including ovary, placenta and embryonic stem cells.
During the past three years, Dr. Vanderhyden has served on grants review panels for the Canadian Institute for Health Research, the Canadian Cancer Society Research Institute, the Cancer Research Society and the European Commission. She is currently on the editorial boards for the Journal of Ovarian Research and BMC Cancer. She is a recent President of the Society for the Study of Reproduction and is Chair of the Study Committee of the TFRIfunded COEUR (national ovarian cancer biomarker) project. She is a member of the board of directors of Ovarian Cancer Canada and the Chair of their Research Committee.
Scientific Breakthroughs:
The Vanderhyden lab has considerable expertise in model development and was the first to generate an in vivo model to study the rarest form of ovarian cancer, small cell carcinoma of the ovary, suitable for therapeutic testing. They reported the first syngeneic mouse model of high-grade serous ovarian cancer, the most common and deadly form of this type of cancer. The Vanderhyden lab was also the first to report a method to isolate the stem/ progenitor cells present in the ovarian epithelium.
Teaching Accomplishments / Awards: Dr. Vanderhyden is a recipient of the Dr. J. David Grimes Research Career Achievement Award, the Capital Educator’s Award and the Governor General’s Caring Canadian Award.
Grant Support: Research in the Vanderhyden lab is funded by grants from the Canadian Institute for Health Research, the Cancer Research Society and the Canadian Cancer Society Research Institute
The Vanderhyden lab studies many aspects of ovarian cancer, including the role of specific genes in human ovarian cancer initiation, progression, chemo-sensitivity and prognosis. They create model systems of ovarian cancer to study disease initiation and to test the therapeutic efficacy of novel anti-cancer drugs. They are particularly interested in the role of stem cells in the ovarian and oviductal epithelia and their contribution to cancer initiation. With a growing interest in chromatin remodeling proteins, they are exploring the roles of these proteins in reproductive tissues, including ovary, placenta and embryonic stem cells.
During the past three years, Dr. Vanderhyden has served on grants review panels for the Canadian Institute for Health Research, the Canadian Cancer Society Research Institute, the Cancer Research Society and the European Commission. She is currently on the editorial boards for the Journal of Ovarian Research and BMC Cancer. She is a recent President of the Society for the Study of Reproduction and is Chair of the Study Committee of the TFRIfunded COEUR (national ovarian cancer biomarker) project. She is a member of the board of directors of Ovarian Cancer Canada and the Chair of their Research Committee.
Scientific Breakthroughs:
The Vanderhyden lab has considerable expertise in model development and was the first to generate an in vivo model to study the rarest form of ovarian cancer, small cell carcinoma of the ovary, suitable for therapeutic testing. They reported the first syngeneic mouse model of high-grade serous ovarian cancer, the most common and deadly form of this type of cancer. The Vanderhyden lab was also the first to report a method to isolate the stem/ progenitor cells present in the ovarian epithelium.
Teaching Accomplishments / Awards: Dr. Vanderhyden is a recipient of the Dr. J. David Grimes Research Career Achievement Award, the Capital Educator’s Award and the Governor General’s Caring Canadian Award.
Grant Support: Research in the Vanderhyden lab is funded by grants from the Canadian Institute for Health Research, the Cancer Research Society and the Canadian Cancer Society Research Institute
Lilian T. Gien,MD, MSc, FRCSC,
Dr. Lilian Gien is a gynecologic oncologist at the Odette Cancer Center, Sunnybrook Health Sciences Center. She is an Associate Professor at the University of Toronto and is currently the Gynecologic Cancer Site Group Chair at the Odette Cancer Centre. Dr. Gien is also an Adjunct Scientist at the Institute for Clinical Evaluative Sciences (ICES) where her research interests in health services research evaluate the effects of healthcare delivery on outcomes in gynecologic malignancies. She is also involved in clinical trial design of rare gynecologic malignancies and is the Principal Investigator for several trials funded by the US National Cancer Institute. Dr. Gien was awarded the GOG Scholar Investigator Award in 2019, a 5-year award dedicated towards clinicaltrial development in gynecologic oncology in the US. She is also the Chair of the Gynecologic Oncology Subspecialty Committee at the Royal College of Physicians and Surgeons of Canada.
Shannon Salvador, MD, Jewish General Hospital
Dr Salvador arrived in Montreal in 2013 following her training in Vancouver with a strong focus on minimally invasive surgical techniques for the treatment of gynecologic cancers. She is currently the head of the Society of the Gynecologic Oncology of Canada Communities of Practise and mentors14 CoP groups across Canada, each with specific goals, research, and interest in forwarding the care of women with gynecologic cancers. At the Jewish General Hospital, she is the Head of Colposcopy and is currently on the board of the Society of Canadian Colposcopists as well as a member of the“Quebec dépistage cancer du col de l'utérus”. She holds an Assistant Professorship position at McGill University where she is the Program Director for the Gynecologic Oncology Royal College training program. Her current research endeavours focus on molecular analysis of endometrial cancers and screening testing for cervical cancers.
Liat Hogen, MD, Gynecologic Oncology at UHN, Toronto
Gyn oncologist at University Health Network and Sinai Health System Assistant Professor, University of Toronto co-lead GOC CoP in immunotherapy for gyn malignancies. Research interestin endometriosis related ovarian cancer and development of predictive models for successful debulking in advanced ovarian cancer patients.
Sydney McQueen, BSc, MSc, MD/PhD Candidate, University of Toronto
Sydney McQueen is an MD/PhD student at the University of Toronto. She previously completed a BSc in Life Science and Neuroscience at Queen’s University, and an MSc in Health Science Education at McMaster University. Sydney’s doctoral work is focused on understanding surgeon stress. Other research interests include resident assessment and feedback, and competency-basededucation.
Carol-Anne Moulton, MD, PhD, Staff Surgeon at University Health Network
Dr. Carol-anne Moulton is an Associate Professor in the Department of Surgery, University of Toronto and Staff Surgeon with the Division of General Surgery, University Health Network. She is currently the Medical Director of the Operating Room in Toronto General and Princess Margaret Hospitals and a Researcher in the Wilson Centre. Dr. Moulton's research program focuses on understanding the complexity of surgical judgment, the development of surgical expertise, and underlying causes of surgeon error.
Julie Nguyen, Assistant Professor, Obstetrics & Gynecology, Faculty of Health Sciences, McMaster University
Julie My Van Nguyen is an Assistant Professor in the Department of Obstetrics and Gynecology at McMaster University and an attending physician in the Division of Gynecologic Oncology at the Juravinski Hospital and Cancer Centre. Upon completing a Masters of Science in Healthcare Improvement and Patient Safety, Julie has led several multidisciplinary perioperative improvement projects, including initiatives to decrease surgical site infections and thromboembolic events after Gynecologic Oncology surgery as well as an opioid stewardship strategy. The focus of her clinical research uses local and North American perioperative data (NSQIP), and provincial-level data (ICES) to define the impact of frailty on postoperative outcomes and completion of chemotherapy in Gynecologic Oncology patients. The overarching goal of her work is to establish evidence to support the implementation of optimization and prehabilitation strategies for frail patients with gynecologic malignancies starting chemotherapy or planned for surgery.
Karla Willows, Assistant Professor; Division of Gynaecologic Oncology
Nazila Azordegan, MD, FRCPC, Gynecologic Pathologist - University of Manitoba
I completed Anatomical pathology residency at the University of Manitoba (2014) and Gynecologic Pathology fellowship at the University of Toronto and UBC (2016); I have been working as Assistant professor at the University of Manitoba since 2014.
David Huntsman, MD, FRCPC, Pathologist, UBC and Scientific Director OvCaRe BC
David Huntsman is a pathologist and clinical molecular geneticist. He leads OvCaRe, BC's multidisciplinary ovarian cancer research team. His research team provided a blueprint for subtype specific research and care and discovered the key mutations in several ovarian cancer subtypes.
Featured ePoster and ePoster abstract presenters
Alicia Tone, PhD, Scientific Advisor at Ovarian Cancer Canada
Alicia joined the Ovarian Cancer Canada team as Scientific Advisor in May 2019, and became OvCAN Project Manager the following November. Her deep well of experience in the ovarian cancer field includes a Ph.D. in ovarian cancer biology from the University of Toronto, postdoctoral studies in ovarian cancer genomics at B.C. Cancer Agency, and more than seven years as Scientific Associate in the Division of Gynecologic Oncology at the Princess Margaret Cancer Centre.
Andra Nica, MD MSc FRCSC,Gyn Oncology Fellow at the University of Toronto
Dr. Andra Nica is a Gynecologic-Oncology Clinical Fellow at the University of Toronto. She obtained her medical degree at Western University in 2013, and then completed her Obstetrics and Gynecology residency training at the University of Toronto in 2018. Subsequently, she pursued a fellowship in Gynecologic Oncology at The University of Toronto and a Masters in ClinicalEpidemiology at the Institute of Health Policy, Management and Evaluation. Her clinical and research interests include cancers of the lower reproductive tract (vulva, cervix) and large scale epidemiological studies in cancers of the endometrium
Christa Aubrey, MD, MSc, FRCSC, Gynecologic Oncology Fellow, University of Calgary
Christa Aubrey completed her medical school and residency training at the University of Alberta, and also completed the Clinician Investigator Program there as well. She is now in her final year offellowship in Gynecologic Oncology at the University of Calgary.
Cristina Mitric,MDCM, BSc, 5th year OBGYN resident, McGill University
Dr Cristina Mitric is a 5th year Obstetrics and Gynecology resident at McGill University, where she completed her medical studies and an undergraduate degree in neuroscience. Starting July 2021, she will begin her Gynecology Oncology fellowship training at the University of Toronto.
Elisabeth Spenard, Clinical Fellow at University of Toronto
Elisabeth Spénard is a first-year clinical fellow in Gynecologic Oncology at the University of Toronto. She completed her residency program in Obstetrics & Gynecology at the Université de Montréal, from which she graduated in 2020. In parallel with her fellowship program, she is currently pursuing a Master’s in Quality Improvement and Patient Safety at the Institute of Health Policy, Management and Evaluation (IHPME) of the Dalla Lana School of Public Health.
Geneviève Bouchard-Fortier, MD, MSc, FRCSC, Gynecologic Oncologist University Health Network
Dr. Genevieve Bouchard-Fortier is a graduate of McGill University. She completed a residency program in the Department of Obstetrics and Gynaecology at the University of Toronto. During this time, Dr. Bouchard-Fortier also obtained a Master of clinical epidemiology focusing on cancer screening and cancer prevention at the Harvard School of Public Health. She completed her fellowship in Gynecologic Oncology at the University of Toronto. During that time, she worked on the outcomes of minimally invasive surgeries for gynecologic oncology patients. More recently, she completed a certificate in patient safety and quality improvement with the Center for Quality Improvement and Patient Safety (CQUIPS) and she is currently completing an Improvement fellowship with CQUIPS. Dr. Bouchard-Fortier research and clinical interests include management of gestational trophoblastic disease as well as development of quality metrics to improve gynecologic oncology care.
Jenna Shirley, MD, ObSgyne Resident at the University of Manitoba
Jenna Shirley is from Saskatoon, Saskatchewan. She completed a Bachelor of Science and Medical degree through the University of Saskatchewan, where the majority of her medical training was done in Regina. Since that time she has been working on her residency training in Winnipeg, Manitoba,and is currently in her fourth year. This includes being one of the two current chief residents. She aspires to practice general obstetrics and gynecology in a rural, or community setting after completing her training.
Joni Kristin Kooy, MD, Gynecologic Onc Fellow at Tom Baker Cancer Centre
Joni Kooy is a Gynecologic Oncology Fellow at Tom Baker Cancer Centre in Calgary. She completed medical school through the University of British Columbia and Obstetrics and Gynecology residency at the University of Calgary. She holds a Master of Science in Healthcare Quality and Patient safety and is interested in improving all aspects of care for Gynecologic Oncology patients with a focus on peri-operative care and endometrial carcinoma.
Leonie Dallaire Nantel, MD, Fellow in Gynecology Oncology Hotel Dieu de Quebec
Doctorate in Medicine Laval University Residency in Gynecology Obstetrics University ofSherbrooke
Luke MacLean, MHSc, MD/PhD program, University of British Columbia
Luke J MacLean received his BEng degree in 2016 for mechanical and biomedical engineering at McGill University. He then completed his MHSc in 2018 in clinical engineering at the University of Toronto and is currently pursuing his combined MD/PhD at the University of British Columbia. He has previously worked as an Industrial Engineer for Michelin Tire and as a Clinical Engineering at Toronto General Hospital. His prior research touched on motion capture analysis, surgical robotics and cardiac critical care. His research currently focuses on emerging techniques in surgical navigation. Mr. MacLean is a member of the Clinical Engineering Society of Ontario, a junior member of the order of Engineers of British Columbia and a junior member of the College of Physicians and Surgeons of British Columbia. He received the University of Toronto Director’s Innovation Award in 2016, the UBC Clinician-Investigator Fellowship in 2018 and the NSERC Alexander Graham Bell CGS-D award in 2021.
Oleksandra Dzyubak, Resident, OB/GYN Resident at Western University
Oleksandra Dzyubak is a PGY-4 resident in Obstetrics and Gynaecology at Western University. She received an Honours Specialization in Medical Sciences in 2012. She completed medical school at the Schulich School of Medicine and Dentistry in 2017. She has an interest in pursuing a fellowship in Gynecologic Oncology.
Rachel Soyoun Kim, Gynecology Oncology Fellow
Dr Rachel Kim is a gynecology oncology fellow at University of Toronto. Research interests includecancer genomics and hereditary malignancies.
Sabrina Piedimonte, MDCM, MSc, FRCSC , Gynecologic Oncology Fellow, University of Toronto
Sabrina Piedimonte is a first-year fellow in gynecologic oncology at the University of Toronto. She holds a B.Sc. in Microbiology and Immunology, M.Sc. in Experimental Surgery and MD CM from McGill University. She completed her residency in obstetrics and gynecology at McGill University in 2020 and during that time received the Eric and Jane Molson award for Excellence in Research and Brian Newton award in Gynecologic Oncology. Previous research has included development ofa predictive score to reduce false positives in ovarian cancer testing, implementation of gynecologic oncologist-initiated germline BRCA testing and development of HPV vaccination clinics and adecision-aid tool. She recently completed the Program in Clinical Effectiveness, a joint Harvard/Brigham and Women’s Hopsital/Massechussetts General Hospital certificate in August 2020 with focus in predictive modeling, machine learning and survival analysis. Her current research interests include improving precision in advanced ovarian cancer with the development of aprediction model for cytoreductive outcome and a photo-documentation study, application of machine learning in gynecologic oncology and prevention of cervical cancer with HPV vaccination and education.
Sarah Mah, MD, FRCSC, Gynecologic Oncology Fellow at McMaster University
Sarah Mah is a Gynecologic Oncology fellow at McMaster University and concurrently undertakingher MSc in Quality Improvement and Patient Safety through the University of Toronto Institute ofHealth Policy, Management and Evaluation. She completed her residency at the University ofBritish Columbia
Armaghan Wasim, Medical Student at University of Saskatchewan
Armaghan Wasim is a 2nd year medical student at the College of Medicine, University of Saskatchewan. After initially enrolling in Pharmacy in his undergraduate years, Armaghan ultimately decided to pursue Medicine as a career path. This project was completed under the supervision of Dr. Shaina Lee, a gynecologic oncologist and an associate professor with the Faculty of Medicine, University of Saskatchewan. The research project was sponsored as a University of Saskatchwan Dean’s Project Award.
Yue Yin Xia, BSc, MSc student at The University of Toronto
Yue Yin Xia's research area of expertise focuses on hereditary breast and ovarian cancer and novel strategies for cancer prevention. Currently she is investigating the relationship between contemporary types of contraception and ovarian cancer risk among BRCA1 and BRCA2 mutationcarriers. Women with an inherited BRCA1 or BRCA2 mutation face a high lifetime risk of developing ovarian cancer. While surgical removal of the fallopian tubes and ovaries (bilateralsalpingo-oophorectomy) is the most effective cancer prevention strategy, oral contraceptive use isthe only effective nonsurgical protective factor and chemoprevention option. Changes incontraceptive formulations and patterns of use over time have introduced lower hormonal dosages,new hormone types and non-oral routes of administration. To date, there have been no prospective analyses of this relationship, and the impact of other types of contraception on BRCA-associated ovarian cancer risk remains unclear. For her master's project, she will investigate the relationship between types of contraception and ovarian cancer incidence through a longitudinal study of BRCA1 and BRCA2 mutation carriers Yue Yin Xia is a Master of Science student in the Department of Pharmacology and Toxicology at the University of Toronto. Her work may ultimately inform clinical recommendations surrounding the use of contraceptive agents forchemoprevention in high-risk women.
Madison Bittner, University of British Columbia
Completed BSc at the University of Victoria in Biochemistry. Currently pursuing a masters in Reproductive and Developmental Science at the University of British Columbia
Raymond John Osborne, MD, FRCSC, MBA,
MD, U of T, 1970 FRCSC 1975 Fellowship in Gyn Oncoligy, Mr. Stanley Way, UK 1976-1977Fellowship Gyn Oncology, McMaster U 1984-1986
Susan Dong,BHSc, Medical Student at University of Toronto
Susan is a third-year medical student at the University of Toronto’s Temerty Faculty of Medicine.Susan has developed an earnest passion for women’s health, particularly with an intersectionality onhealth and gender equity in mind. After learning about delayed identification and poor survival outcomes of many gynaecological malignancies, she organized patient panels featuring ovarian cancer survivors for her medical class in order to promote awareness of this insidious disease; She also continues to leverage her research pursuits to identify and shed light on gaps in screening, early identification, and management of gynaecological malignancies to improve outcomes for patients regardless of their age, race, and socioeconomic status.
Jaclyn Hynes, MSc, Memorial University of Newfoundland
Jaclyn Hynes is a graduate of Memorial University with an MSc in Clinical Epidemiology. Her research work focuses on exploring the lived experiences of BRCA mutation carriers in Newfoundland Labrador.
Caitlin Lazurko, MSc, University of Toronto, Faculty of Medicine
Caitlin is a second-year medical student at the University of Toronto. Prior to medical school, she completed her Master of Science in biochemistry at the University of Ottawa where her research focused on using biomaterials and nano materials for the treatment of nonhealing wounds. Outside ofa cademia, Caitlin enjoys running, crafting, and spending time with friends and family.
Juliette Bernard, MD, Gynecologic oncologist at The Grenoble Hospital
French gynecologist who completed a fellow in gynecology-oncology in Quebec, QC (2019-2021)
Sandipan Chowdhuri, MD, Gynecologic Oncology trainee at AIIMS Rishikesh
Currently pursuing MCh Gynaecological Oncology from All India Institute Of Medical Sciences,Rishikesh academic session July 2018. I have joined on 13th July 2018 and will finish on 12th July2021. Finished Post-Doctoral Fellowship course in Gynaecologic Oncology in CHRISTIAN MEDICAL COLLEGE VELLORE. Course duration is 2 years. Course approved by Tamil Nadu Dr.M.G.R. Medical University. Christian Medical College Vellore is one of the best colleges in India inregards to training and patient management. DNB Obstetrics & Gynecology passed in Jun 2015. MS in Gynaecology & Obstetrics from Medical College, Kolkata tenure from 9th May 2011 to 8th May 2014. Internship from Medical College, Kolkata (2009-2010). MBBS from Medical College, Kolkata (2004-2009)
Marilyn Kinloch, MD, Pathologist at Sask
Dr. Kinloch is the division head for Anatomic Pathology for the Saskatchewan Health Authority in Saskatoon. She completed her medical school at the National University of Ireland, in Dublin, her residency in General Pathology at the U of S with a fellowship in gynecologic pathology from UBC. She is employed as a subspecialty pathologist and a clinical associate professor at the University of Saskatchewan in the department of pathology and laboratory medicine. Her research is primarily on the molecular classification of endometrial carcinoma and quality improvement and standardization work within anatomic pathology including tissue preservation in lung biomarker assessment in patients with advanced lung adenocarcinoma. Locally, she sits as the co-chair for anatomic pathology in the province, the vice president for the Saskatoon Regional Medical Association, and volunteer chair for the Women Leading Philanthropy campaign for the Royal University Hospital Foundation. Her work nationally is through her role on the executive of both the Special Interest Group for Gynecologic Pathology and as a board member for the Canadian Association of Pathologists. Internationally she is a member of the education committee for the International Association of Pathology.
bottom of page